All patients were diagnosed in their first chronic phase and all of them achieved complete cytogenetic response (CCyR
) at 12 months of imatinib treatment.
(By comparison, CCyR
occurs at approximately 10%-1%) A Complete Molecular Response (CMR) is defined as when BCRABL fusion transcripts are no longer detectable; with methods commonly employed, this limit of detection corresponds to around a 5 log decrease in load from pre-treatment levels or 0.001%.
Cytogenetic responses (for both karyotyping and FISH) were classified based on the percentage of Ph-positive metaphases: CCyR
(0%), partial (PCyR; 1%-35%), major (0%-35%), minor (36%-65%), or minimal (66%-95%).
at 6 months and/or BCR-ABL below I% following 6 months of second-generation TKIs are considered as optimal.
In a study conducted by Rosti et al., newly diagnosed chronic phase CML patients treated with nilotinib showed a CCyR
in 96% of the cases after 12 months of initial treatment.
(3) Responses were significantly in favour of imatinib, with a CHR rate at 18 months of 97% versus 69%, a major cytogenetic response (MCyR) rate of 87% versus 34.7%, and a CCyR
rate of 72.6% versus 14.5% in the imatinib and low-dose cytarabine plus interferon arms, respectively.
Patients responding to bosutinib achieved CCyR
faster than those responding to imatinib (13 weeks vs.
Hematological response was obtained after one month, and at three months bone marrow evaluation showed a complete cytogenetic response (CCyR
), together with a BCRABL1 transcript level of 0.2% according to the International Scale (IS).
Of the 402 patients with baseline KD mutations, 14 had F317L mutations; 13 (93%), 2 (14%), and 1 (7%) achieved CHR, major cytogenetic response (MCyR), and complete cytogenetic response (CCyR
The Civic Coalition of Revolutionary Youth (CCYR
) explained: "We reject any forces' attempt to impose the initiative terms on the revolutionary Youth in the squares, and we call these forces to lift its control and monopoly in representation of the revolution and responsibly deal with youth demands." The combative weeks following Saleh's meaningless signature have evaporated any hope lingering over the GCC's current proposal.
7 June 2010 - US Bristol-Myers Squibb Company (NYSE: BMY) and Japanese Otsuka Pharmaceutical Co Ltd, a wholly owned subsidiary of Otsuka Holdings Co Ltd, on Saturday reported Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response (CCyR
) compared to Gleevec (imatinib mesylate).
In addition, Tasigna also showed a statistically significant improvement over Gleevec in every other measure of efficacy in the trial, including major molecular response (MMR) and complete cytogenetic response (CCyR
) at 12 months.A